About bolt biotherapeutics inc - BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
BOLT At a Glance
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City, California 94063
| Phone | 1-650-665-9295 | Revenue | 7.70M | |
| Industry | Pharmaceuticals: Major | Net Income | -33,376,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 0.065% | |
| Fiscal Year-end | 12 / 2026 | Employees | 23 | |
| View SEC Filings |
BOLT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.329 |
| Price to Book Ratio | 0.396 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.165 |
| Enterprise Value to Sales | 0.712 |
| Total Debt to Enterprise Value | 4.191 |
BOLT Efficiency
| Revenue/Employee | 334,565.217 |
| Income Per Employee | -1,451,130.435 |
| Receivables Turnover | 7.909 |
| Total Asset Turnover | 0.095 |
BOLT Liquidity
| Current Ratio | 3.567 |
| Quick Ratio | 3.567 |
| Cash Ratio | 3.285 |
BOLT Profitability
| Gross Margin | 80.624 |
| Operating Margin | -450.071 |
| Pretax Margin | -433.736 |
| Net Margin | -433.736 |
| Return on Assets | -41.196 |
| Return on Equity | -79.749 |
| Return on Total Capital | -67.477 |
| Return on Invested Capital | -52.646 |
BOLT Capital Structure
| Total Debt to Total Equity | 86.618 |
| Total Debt to Total Capital | 46.414 |
| Total Debt to Total Assets | 36.789 |
| Long-Term Debt to Equity | 75.955 |
| Long-Term Debt to Total Capital | 40.701 |